Shares of Irvine-based Edwards Lifesciences Corp. are up slightly after yesterday's report of second-quarter earnings and revenue that beat Wall Street expectations and reaffirmed its outlook.
The heart valve maker posted a profit of $94 million, up 38% from 2012’s first quarter. Analysts expected Edwards’ profit to be $87.2 million.
Revenue grew 7% to $517 million. Wall Street was looking for sales of $514.7 million.
Edwards noted that sales of its less-invasive transcatheter heart valves rose 25% to $182 million. The hike was mainly driven by the ongoing domestic introduction of Edwards Sapien, which accounted for $90 million in sales from about 250 commercial sites.
Edwards also reaffirmed its 2013 full-year outlook.
The device maker could see a profit of $344.1 million to $355.6 million, based on a share count of 114.7 million outstanding.
Analysts estimate Edwards will post a 2013 profit of $351 million.
Edwards said it expects full-year sales of $2 billion to $2.1 billion, in line with the Wall Street consensus of $2.05 billion.
The device maker released its financial results after the close of trading today. Edwards’ shares were up about 1% to a market value of about $8.1 billion in early trading today.